Bronchogen

Bronchogen (H-Ala-Asp-Glu-Leu-OH; ADEL tetrapeptide; molecular formula C18H30N4O9; molecular weight 446.45 g/mol) is a synthetic tetrapeptide bioregulator developed by Vladimir Khavinson and colleagues at the Saint Petersburg Institute of Bioregulation and Gerontology as the bronchopulmonary-specific member of the Khavinson ultrashort peptide bioregulator family [1, 2]. The compound belongs to a class of synthetic two-to-seven-residue peptide sequences modeled on tissue-specific peptide fragments isolated from mammalian organ extracts, and is designated as the respiratory system bioregulator within this peptide family. Bronchogen is structurally related to but distinct from the other Khavinson tetrapeptides that share the Ala-Glu-Asp tripeptide core (Cardiogen, Cortagen, Epithalon); the ADEL sequence carries a different arrangement of the acidic residues (Asp at position two, Glu at position three) and a hydrophobic leucine residue at the C-terminus, a configuration that determines bronchial tissue specificity within the Khavinson classification system [3, 4]. The principal molecular mechanism of Bronchogen, characterized through molecular modeling, cell culture, organotypic bronchial tissue studies, and animal models of obstructive lung disease, is epigenetic regulation of gene expression through direct interaction of the tetrapeptide with double-stranded DNA and with histone proteins, producing chromatin remodeling and reactivation of transcriptional programs in bronchial epithelial cells [5, 6, 7]. The bronchopulmonary activity, characterized in organotypic lung tissue cultures from young and aged rats, human bronchial epithelial cell cultures across multiple passages, and nitrogen dioxide-induced chronic obstructive pulmonary disease (COPD) rat models, includes stimulation of bronchial epithelial cell proliferation and differentiation with upregulation of differentiation markers in aging cell cultures [8, 9], regulation of Ki67, Mcl-1, p53, CD79, and endothelial nitric oxide synthase (NOS-3) protein expression in human bronchial epithelium [5], restoration of normal ciliated epithelial architecture with reduction of goblet cell hyperplasia and squamous metaplasia in COPD models [10], normalization of proinflammatory cytokine profiles and neutrophilic inflammation in bronchoalveolar lavage fluid [10, 11], and enhancement of secretory immunoglobulin A and surfactant protein B production indicating recovery of respiratory mucosal barrier and surfactant function [11]. No formal pharmacokinetic studies have been published for Bronchogen as the isolated synthetic ADEL tetrapeptide. As a linear tetrapeptide with unprotected termini, the compound is expected to undergo rapid proteolytic degradation by aminopeptidases and carboxypeptidases in plasma and gastrointestinal fluid; however, molecular modeling studies have demonstrated that ultrashort peptides are substrates of the proton-coupled oligopeptide transporter (PEPT1/PEPT2) family carriers, supporting intestinal absorption and cellular uptake through active transport mechanisms [12, 13]. No human clinical trials have been published. The compound is not approved by the United States Food and Drug Administration, the European Medicines Agency, or any major Western regulatory authority. Bronchogen is registered in the Russian Federation as a biologically active additive and is commercially available there in capsule formulations. It is supplied internationally as a research-grade lyophilized peptide by multiple peptide synthesis vendors at greater than 95 percent purity by high-performance liquid chromatography. This monograph reviews the chemistry, synthesis, and structural characterization of Bronchogen; the discovery and development history within the Khavinson bioregulatory peptide program; the molecular pharmacology including peptide-DNA binding, histone interaction, and bronchial gene expression modulation; the pharmacokinetic considerations for ultrashort peptides; the preclinical pharmacology across bronchial, inflammatory, and aging cell models; the clinical evidence base (absent); sourcing and quality verification; reconstitution and handling; stack interactions and combinations; adverse events and safety signal; and a comparative assessment of five bronchopulmonary or respiratory-protective peptide candidates (Chonluten, GHK-Cu, BPC-157, Thymalin, N-acetylcysteine) against Bronchogen on five competency standards.